Eva Galante studied biomolecular chemistry at the University of Catania, Italy. As a postgraduate she won a 2004 research fellowship at the Consiglio Nazionale delle Ricerche (CNR), where she investigated natural products chemistry and was awarded “Best National Project” for achievement and technological innovation.
In 2010, Eva was awarded a PhD in chemical science from the University of Catania, where she had worked on the development of anti-tumour vaccine candidates based on tumour-associated glycomimetic antigens. As part of her doctoral programme, she spent a year at the John Innes Centre in Norwich researching new glycoconjugates acting as anti-parasite against Trypanosoma cruzi.
Eva served as a postdoctoral researcher at the University College of London, contributing to several multidisciplinary projects covering nuclear medicine, bioimaging and neurology. Her main projects focused on diagnosis of epilepsy and on the development of new chemotherapeutics against neuroblastoma.
After serving as a teaching fellow in chemistry at Queen Mary University of London, she was appointed lecturer in chemistry at the University of East London.
Dr Galante's primary research interest lies in medicinal chemistry, with particular focus on medicinal chemistry and natural products.